Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLOW4: NVA237 vs Tiotropium in Japanese COPD Patients
NCT01119937Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2010
- Primary completion
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of glycopyrronium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Novartis. Primary endpoint: Number of Participants With Adverse Events, Serious Adverse Events or Death at 52 weeks. Started May 2010; status: completed.
02
Drugs
glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01119937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01119937.